Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-16EMA Authorised: Elrexfio (elranatamab) — Pfizer Europe MA EEIG
The EMA authorised Elrexfio (elranatamab) for multiple myeloma under conditional approval by Pfizer Europe MA EEIG.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update describing a Phase 1/2 study evaluating the combination of talquetamab and teclistamab in relapsed or refractory mul…
-
CLINICAL_TRIALS other · 2026-01-16Clinical Trial Update: A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 2]
A Phase 2, single-arm multicenter clinical trial evaluating a triplet regimen of mezigdomide, carfilzomib, and dexamethasone (480Kd) in rela…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Removing Transfusion Dependence as a Barrier to Hospice Enrollment [NA]
A completed clinical trial update indicates that transfusion dependence was removed as a barrier to hospice enrollment for patients with hem…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study [EARLY_Phase 1]
Early-phase 1 pilot study investigating PET imaging of cancer patients with the radiopharmaceutical 124I-PUH71, with the trial status curren…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
This document updates the status of a clinical trial evaluating Selinexor (Nexpovio) in relapsed or refractory multiple myeloma, indicating …
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]
An early-phase study evaluating sotatercept (ACE-011) in combination with lenalidomide or pomalidomide and dexamethasone for relapsed/refrac…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating isatuximab in combination with belantamab mafodotin, pomalidomide, and dexamethasone for relapsed/refractory multip…
-
CLINICAL_TRIALS withdrawal · 2026-01-14Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]
The Phase 1 trial evaluating intravenous TAK-573 in combination therapy for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype [Phase 1]
A Phase 1 trial evaluating dose modifications of systemic anti-cancer therapy in individuals with the Duffy null phenotype. The study enroll…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial of PHE885 CAR-T Therapy for adults with relapsed and refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial update indicates that JY232 injection is being studied for relapsed/refractory multiple myeloma and …
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Isa-VRD in TIE HRMM [Phase 4]
Phase 4 trial update for Isa-VRD in multiple myeloma; the study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma [Phase 2]
Phase 2 trial evaluating upfront CAR-T cell therapy to upgrade response in multiple myeloma; results have been posted for this completed stu…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating naive HBI0101 CAR-T therapy in relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease [Phase 2]
Phase 2 clinical trial evaluating a triple combination of mezigdomide, carfilzomib, and dexamethasone for relapsed or refractory multiple my…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Moving Foward With Myeloma (MFM) [NA]
The update indicates plans to move forward with a multiple myeloma trial led by the Medical College of Wisconsin, which is not yet recruitin…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments [Phase 2]
A Phase 2 clinical trial in multiple myeloma is evaluating sequential therapy guided by minimal residual disease (MRD) assessments. The stud…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD) [NA]
A clinical trial updating on the mechanisms of clonal and non-clonal cytopenia after CAR-T cell therapy in patients with multiple myeloma or…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: A Study of NINLARO® in Chinese Adults With Multiple Myeloma
This clinical trial update reports the status of a study evaluating NINLARO (ixazomib) in Chinese adults with multiple myeloma; the trial is…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse [Phase 2]
This Phase 2 clinical trial update examines linvoseltamab plus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma to de…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial evaluating palifermin in combination with leuprolide acetate to promote immune recovery after total body irradiation-…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager [Phase 4]
Phase 4 clinical trial update describing the use of immunoglobulin therapy in multiple myeloma patients treated with a BCMA-directed T cell …
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: IASO206 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial of IASO206 for relapsed/refractory multiple myeloma is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Non-invasive MRD Assessment in Multiple Myeloma
This document provides an update on a completed clinical trial evaluating a non-invasive method for assessing minimal residual disease in mu…